JP2025087764A5 - - Google Patents

Info

Publication number
JP2025087764A5
JP2025087764A5 JP2025031035A JP2025031035A JP2025087764A5 JP 2025087764 A5 JP2025087764 A5 JP 2025087764A5 JP 2025031035 A JP2025031035 A JP 2025031035A JP 2025031035 A JP2025031035 A JP 2025031035A JP 2025087764 A5 JP2025087764 A5 JP 2025087764A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
antibody
complementarity determining
determining regions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025031035A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025087764A (ja
Filing date
Publication date
Priority claimed from JP2019552040A external-priority patent/JP2020514386A/ja
Priority claimed from PCT/EP2018/057310 external-priority patent/WO2018172465A1/en
Application filed filed Critical
Publication of JP2025087764A publication Critical patent/JP2025087764A/ja
Publication of JP2025087764A5 publication Critical patent/JP2025087764A5/ja
Pending legal-status Critical Current

Links

JP2025031035A 2017-03-22 2025-02-28 ヒト化抗cxcr5抗体を使用するループスの処置 Pending JP2025087764A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762475173P 2017-03-22 2017-03-22
US62/475,173 2017-03-22
EP17306079 2017-08-18
EP17306079.9 2017-08-18
JP2019552040A JP2020514386A (ja) 2017-03-22 2018-03-22 ヒト化抗cxcr5抗体を使用するループスの処置
PCT/EP2018/057310 WO2018172465A1 (en) 2017-03-22 2018-03-22 Treatment of lupus using humanized anti-cxcr5 antibodies
JP2023003470A JP2023040241A (ja) 2017-03-22 2023-01-13 ヒト化抗cxcr5抗体を使用するループスの処置

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2023003470A Division JP2023040241A (ja) 2017-03-22 2023-01-13 ヒト化抗cxcr5抗体を使用するループスの処置

Publications (2)

Publication Number Publication Date
JP2025087764A JP2025087764A (ja) 2025-06-10
JP2025087764A5 true JP2025087764A5 (cg-RX-API-DMAC7.html) 2025-10-21

Family

ID=61827719

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019552040A Pending JP2020514386A (ja) 2017-03-22 2018-03-22 ヒト化抗cxcr5抗体を使用するループスの処置
JP2023003470A Pending JP2023040241A (ja) 2017-03-22 2023-01-13 ヒト化抗cxcr5抗体を使用するループスの処置
JP2025031035A Pending JP2025087764A (ja) 2017-03-22 2025-02-28 ヒト化抗cxcr5抗体を使用するループスの処置

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2019552040A Pending JP2020514386A (ja) 2017-03-22 2018-03-22 ヒト化抗cxcr5抗体を使用するループスの処置
JP2023003470A Pending JP2023040241A (ja) 2017-03-22 2023-01-13 ヒト化抗cxcr5抗体を使用するループスの処置

Country Status (7)

Country Link
US (1) US20240207397A1 (cg-RX-API-DMAC7.html)
EP (1) EP3601344A1 (cg-RX-API-DMAC7.html)
JP (3) JP2020514386A (cg-RX-API-DMAC7.html)
KR (2) KR20250052493A (cg-RX-API-DMAC7.html)
CN (1) CN110662767A (cg-RX-API-DMAC7.html)
AU (1) AU2018238540B2 (cg-RX-API-DMAC7.html)
IL (2) IL318907A (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023010483A1 (en) * 2021-08-05 2023-02-09 Hifibio (Hk) Limited Anti-human cxcr5 antibody and uses thereof
KR20230004472A (ko) * 2020-04-21 2023-01-06 리제너론 파마슈티칼스 인코포레이티드 인간화 cxcl13 유전자를 갖는 비인간 동물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2195023B1 (en) * 2007-08-29 2018-03-07 Sanofi Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
WO2012010582A1 (en) * 2010-07-21 2012-01-26 Roche Glycart Ag Anti-cxcr5 antibodies and methods of use
MX2017002381A (es) * 2014-08-22 2017-09-15 Sorrento Therapeutics Inc Proteinas de union de antigeno que se unen a cxcr5.

Similar Documents

Publication Publication Date Title
JP2025111463A5 (cg-RX-API-DMAC7.html)
JP2021526022A5 (cg-RX-API-DMAC7.html)
JP2008529497A5 (cg-RX-API-DMAC7.html)
JP2011502137A5 (cg-RX-API-DMAC7.html)
JP2023093753A5 (cg-RX-API-DMAC7.html)
JP2012532851A5 (cg-RX-API-DMAC7.html)
JP2024506315A5 (cg-RX-API-DMAC7.html)
JP2024024114A5 (cg-RX-API-DMAC7.html)
JP2023510982A5 (cg-RX-API-DMAC7.html)
CN112654640A (zh) 抗IL-1β的抗体、其药物组合物及其用途
JP2024540148A5 (cg-RX-API-DMAC7.html)
WO2017059813A1 (zh) 抗乙肝表面抗原的抗体及其用途
WO2022228183A1 (zh) 抗siglec15抗体及其制备方法和用途
JP2026508246A (ja) 抗体、抗原結合フラグメント及び使用方法
CN116178530A (zh) 抗体在治疗SARS-CoV-2感染的用途
JP2024534116A5 (cg-RX-API-DMAC7.html)
JP2023040241A5 (cg-RX-API-DMAC7.html)
CN113444177A (zh) 抗IL-1β的抗体、其药物组合物及其用途
CN114605532B (zh) 抗β-淀粉样蛋白抗体及其用途
CN114578066B (zh) 检测β-淀粉样蛋白的产品和方法
TW202108631A (zh) 一種抗cd47抗原結合蛋白及其應用
JP2022527790A5 (cg-RX-API-DMAC7.html)
IL277899B2 (en) Methods and preparations for treating yellow fever
CN114594272A (zh) 用于检测β-淀粉样蛋白的产品和方法
JP2024516621A5 (cg-RX-API-DMAC7.html)